BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36793605)

  • 1. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel.
    Averbuch I; Salman S; Shtamper N; Doweck I; Popovtzer A; Markel G; Hendler D; Finkel I; Moore A; Fenig E; Taha T; Mhameed K; Kurman N; Billan S
    Front Oncol; 2023; 13():1117804. PubMed ID: 36793605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
    Yakobson A; Abu Jama A; Abu Saleh O; Michlin R; Shalata W
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study.
    McLean LS; Lim AM; Bressel M; Lee J; Ladwa R; Guminski AD; Hughes B; Bowyer S; Briscoe K; Harris S; Kukard C; Zielinski R; Alamgeer M; Carlino M; Mo J; Park JJ; Khattak MA; Day F; Rischin D
    Med J Aust; 2024 Feb; 220(2):80-90. PubMed ID: 38212673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.
    Salzmann M; Leiter U; Loquai C; Zimmer L; Ugurel S; Gutzmer R; Thoms KM; Enk AH; Hassel JC
    Eur J Cancer; 2020 Oct; 138():125-132. PubMed ID: 32882466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
    Ashraf S; Alsharedi M
    Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients.
    Van Meerhaeghe T; Baurain JF; Bechter O; Orte Cano C; Del Marmol V; Devresse A; Doubel P; Hanssens M; Hellemans R; Lienard D; Rutten A; Sprangers B; Le Moine A; Aspeslagh S
    Front Nephrol; 2022; 2():1041819. PubMed ID: 37675002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
    Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
    Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
    Benzaquen M
    Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry.
    Haist M; Stege H; Lang BM; Tsochataridou A; Salzmann M; Mohr P; Schadendorf D; Ugurel S; Placke JM; Weichenthal M; Gutzmer R; Leiter U; Kaatz M; Haferkamp S; Berking C; Heppt M; Tschechne B; Schummer P; Gebhardt C; Grabbe S; Loquai C
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
    Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
    Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
    Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
    Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.
    Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; van Akkooi A; Bataille V; Bastholt L; Dreno B; Dummer R; Fargnoli MC; Forsea AM; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NW; Lallas A; Leiter U; Malvehy J; Del Marmol V; Moreno-Ramirez D; Pellacani G; Peris K; Saiag P; Tagliaferri L; Trakatelli M; Ioannides D; Vieira R; Zalaudek I; Arenberger P; Eggermont AMM; Röcken M; Grob JJ; Lorigan P;
    Eur J Cancer; 2023 Nov; 193():113252. PubMed ID: 37708630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 Blockade With Concurrent Radiotherapy for Locally Advanced Inoperable Cutaneous Squamous Cell Carcinoma.
    Joseph K; Walker J; Raziee H; Faruqi S; Smylie M
    J Cutan Med Surg; 2022; 26(3):243-248. PubMed ID: 34866423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study.
    Bailly-Caillé B; Kottler D; Morello R; Lecornu M; Kao W; Meyer E; Dompmartin A; L'Orphelin JM
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
    Lai FY; Clarke R; Cooper P; Stokes J; Calvert P
    Case Rep Oncol; 2023; 16(1):1156-1165. PubMed ID: 37900839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.
    Kim EY; Ruiz ES; DeSimone MS; Shalhout SZ; Hanna GJ; Miller DM; Schmults C; Rettig EM; Foreman RK; Sethi R; Thakuria M; Silk AW
    JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):414-420. PubMed ID: 38546619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre.
    Koch Hein EC; Vilbert M; Hirsch I; Fernando Ribeiro M; Muniz TP; Fournier C; Abdulalem K; Saldanha EF; Martinez E; Spreafico A; Hogg DH; Butler MO; Saibil SD
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma-A Retrospective Single-Center Study.
    Kuzmanovszki D; Kiss N; Tóth B; Tóth V; Szakonyi J; Lőrincz K; Hársing J; Kuroli E; Imrédi E; Kerner T; Patyánik M; Wikonkál NM; Szabó Á; Brodszky V; Rencz F; Holló P
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical treatment of advanced cutaneous squamous-cell carcinoma.
    Gellrich FF; Hüning S; Beissert S; Eigentler T; Stockfleth E; Gutzmer R; Meier F
    J Eur Acad Dermatol Venereol; 2019 Dec; 33 Suppl 8():38-43. PubMed ID: 31833610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California.
    In GK; Vaidya P; Filkins A; Hermel DJ; King KG; Ragab O; Tseng WW; Swanson M; Kokot N; Lang JE; Menendez L; DeClerck B; Kim G; Hu JC; Terando A; Jadvar H; Ricker C; Miller KA; Peng DH; Wysong A
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1803-1811. PubMed ID: 33210210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.